In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Aura Biosciences Inc, with a price target of $22.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors related to Aura Biosciences Inc’s ongoing clinical programs and potential in oncology. The company’s Phase 3 CoMpass trial in early choroidal melanoma is progressing well, with a significant number of clinical sites activated and patients pre-screened. The trial is under a Special Protocol Assessment with the FDA, indicating strong regulatory alignment, and is expected to provide topline data by the fourth quarter of 2027.
Furthermore, Aura Biosciences Inc has received Orphan Drug and Fast Track designations for its bel-sar treatment, which supports its potential effectiveness and importance. The company’s strategic expansion into other oncology areas, such as non-muscle invasive bladder cancer, and the promising early data showing bel-sar’s ability to induce immune responses, further bolster confidence in its platform. These developments suggest a strong potential for value inflection, justifying the Buy rating and a price target of $22.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AURA in relation to earlier this year.